Investors in this space should buy financially strong AR companies with platforms that can drive adoption.
A new kind of software called Robotic Process Automation is coming into its own and Blue Prism hopes to take advantage.
The company has high interest from short-sellers. That's good news because all those shorts will have to buy this rising tech stock.
Whether you want to visit cyberspace or outer space, these companies can get you there.
Which of these SaaS titans is more worthy of your investing dollars?
Here's why you might want to buy Amarin and Blueprint Medicines as soon as possible.
These two pharma micro-caps are approaching climactic phase 3 trials.
See why Afterpay, StoneCo, and Zillow might be the right fintech stocks for you to invest in.
InMode, Amarin, and Arrowhead Pharmaceuticals are small-cap healthcare stocks working wonders right now.
See why Glu Mobile, MeiraGTx, and Enphase Energy should be on your shopping list.
Will Netflix remain the king of all streaming, or will Disney topple the upstart?
It might morph into an incredibly valuable financial services company, or even a super-bank.
The stock market is severely underpricing a gaming stock for your smart phone and a speed-boat manufacturer.
MIrati Therapeutics, Iovance Biotherapeutics, and Personalis are all using genetic knowledge to help find cures for cancer.
This tiny biotech has a long history of failure, but it also has a flu vaccine that is likely to be approved by the FDA.
Microsoft has a flaw, and tiny Smartsheet is taking advantage of it.
This French video-game company's stock has taken a big hit, but we like what it has in store.
It's highly likely that Immunomedics' billion-dollar drug will finally be approved by the FDA.
An online startup is disrupting an industry with a cheaper and easier alternative.
It's an amazing company with fantastic revenue growth. But there's one small problem that's keeping me on the sidelines.